1.      Abbas Z, Afzal R. Life cycle and pathogenesis of hepatitis D virus: A review. World J Hepatol. 2013;5:666–675. doi: 10.4254/wjh.v5.i12.666. 

2.      Asselah T, Loureiro D, Tout I, Castelnau C, Boyer N, Marcellin P, Mansouri A. Future treatments for hepatitis delta virus infection. Liver Int. 2020;40 Suppl 1:54–60. doi: 10.1111/liv.14356.

3.      Boni C, Fisicaro P, Valdatta C, Amadei B, Di Vincenzo P, Giuberti T, Laccabue D, Zerbini A, Cavalli A, Missale G, Bertoletti A, Ferrari C. Characterization of hepatitis B virus (HBV)-specific T-cell dysfunction in chronic HBV infection. J Virol. 2007;81:4215–4225. doi: 10.1128/JVI.02844-06.

4.      Burton AR, Pallett LJ, McCoy LE, Suveizdyte K, Amin OE, Swadling L, Alberts E, Davidson BR, Kennedy PT, Gill US, Mauri C, Blair PA, Pelletier N, Maini MK. Circulating and intrahepatic antiviral B cells are defective in hepatitis B. J Clin Invest. 2018;128:4588–4603. doi: 10.1172/JCI121960.

5.      Ciftci IH, Koroglu M, Demiray T, Terzi HA, Kahraman Kilbas EP. Age-Specific Seroprevalence of Hepatitis A Virus in Turkey Between 2000 and 2023: Systematic Review and Meta-Analysis. Diagnostics (Basel). 2024;14(22):2464. Published 2024 Nov 5. doi:10.3390/diagnostics14222464

6.      Demirtürk N, Köse A, Ural O, et al. Management of chronic hepatitis B infection: A consensus report of the Study Group for Viral Hepatitis of the Turkish Society of Clinical Microbiology and Infectious Diseases-2023 Update. Klimik Derg. 2023;36(Suppl. 1):1-22.

7.      Desai A, Sandhu S, Lai JP, Sandhu DS. Hepatocellular carcinoma in non-cirrhotic liver: A comprehensive review. World J Hepatol. 2019;11:1–18. doi: 10.4254/wjh.v11.i1.1. 

8.      Dhawan A, Taylor RM, Cheeseman P, et al. Wilson’s disease in children: 37-year experience and revised King’s score for liver transplantation. Liver Transpl 2005;11:441-8.

9.      Elsheikh R, Tien HT, Makram AM, Van NT, Le TTB, Vasanthakumaran T, Huy NT. Acute hepatitis of unknown origin in children: Behind the statistics. Hepatology. 2023 Jun 1;77(6):2118-2127. doi: 10.1002/hep.32682. Epub 2022 Aug 9. PMID: 35862247.

10.  European Association for Study of Liver. EASL Clinical Practice Guidelines: Wilson’s disease. J Hepatol. 2012 Mar;56(3):671-85. PMID: 22340672.

11.  European Association for the Study of the Liver. EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection. J Hepatol. 2017;67(2):370-98.

12.  Fanning GC, Zoulim F, Hou J, Bertoletti A. Therapeutic strategies for hepatitis B virus infection: towards a cure. Nat Rev Drug Discov. 2019;18:827–844. doi: 10.1038/s41573-019-0037-0.

13.  Farci P, Anna Niro G. Current and Future Management of Chronic Hepatitis D. Gastroenterol Hepatol (N Y) 2018;14:342–351. 

14.  Ganem D, Prince AM. Hepatitis B virus infection--natural history and clinical consequences. N Engl J Med. 2004;350:1118–1129. doi: 10.1056/NEJMra031087.

15.  Gökhan BAYSOY, Necati BALAMTEKİN; ÇOCUK GASTROENTEROLOJİ, HEPATOLOJİ ve BESLENME DERNEĞİ ÇOCUKLARDA HEPATİT C VİRÜSÜ ENFEKSİYONU TANI VE TEDAVİ REHBERİ https://pedgastro.org/doc/rehber/17-01-2022-1.pdf (Erişim:Kasım 2025)

16.  Hajarizadeh B, Grebely J, Dore GJ. Epidemiology and natural history of HCV infection. Nat Rev Gastroenterol Hepatol. 2013;10:553–562. doi: 10.1038/nrgastro.2013.107.

17.  Heim K, Neumann-Haefelin C, Thimme R, Hofmann M. Heterogeneity of HBV-Specific CD8+ T-Cell Failure: Implications for Immunotherapy. Front Immunol. 2019;10:2240. doi: 10.3389/fimmu.2019.02240

18.  https://hsgm.saglik.gov.tr/tr/asi-takvimi.html

19.  https://www.who.int/news-room/fact-sheets/detail/hepatitis-b [Erişim:14.11.2025]

20.  Kabaçam G, Onder FO, Yakut M, Seven G, Karatayli SC, Karatayli E, Savas B, Idilman R, Bozdayi AM, Yurdaydin C. Entecavir treatment of chronic hepatitis D. Clin Infect Dis. 2012;55:645–650. doi: 10.1093/cid/cis459. 

21.  Kim JD, Cho EJ, Ahn C, Park SK, Choi JY, Lee HC, Kim DY, Choi MS, Wang HJ, Kim IH, Yeon JE, Seo YS, Tak WY, Kim MY, Lee HJ, Kim YS, Jun DW, Sohn JH, Kwon SY, Park SH, Heo J, Jeong SH, Lee JH, Nakayama N, Mochida S, Ido A, Tsubouchi H, Takikawa H, Shalimar , Acharya SK, Bernal W, O'Grady J, Kim YJ. A Model to Predict 1-Month Risk of Transplant or Death in Hepatitis A-Related Acute Liver Failure. Hepatology. 2019;70:621–629. doi: 10.1002/hep.30262.

22.  Kruszon-Moran D, Paulose-Ram R, Martin C, Barker L, and McQuillan, G Prevalence and trends in hepatitis B virus infection in the United States, 2015-2018. NCHS Data Brief. 2020;361:1–8.

23.  Mosley JW, Operskalski EA, Tobler LH, Andrews WW, Phelps B, Dockter J, Giachetti C, Busch MP. Viral and host factors in early hepatitis C virus infection. Hepatology. 2005;42:86–92. doi: 10.1002/hep.20742.

24.  Nelson NP, Link-Gelles R, Hofmeister MG, Romero JR, Moore KL, Ward JW, Schillie SF. Update: Recommendations of the Advisory Committee on Immunization Practices for Use of Hepatitis A Vaccine for Postexposure Prophylaxis and for Preexposure Prophylaxis for International Travel. MMWR Morb Mortal Wkly Rep. 2018;67:1216–1220. doi: 10.15585/mmwr.mm6743a5. 

25.  Odenwald, M. A., & Paul, S. (2022). Viral hepatitis: Past, present, and future. World journal of gastroenterology, 28(14), 1405–1429. https://doi.org/10.3748/wjg.v28.i14.1405

26.  Oh IS, Park SH. Immune-mediated Liver Injury in Hepatitis B Virus Infection. Immune Netw. 2015;15:191–198. doi: 10.4110/in.2015.15.4.191.

27.  Phan C, Hollinger FB. Hepatitis A: Natural history, immunopathogenesis, and outcome. Clin Liver Dis (Hoboken) 2013;2:231–234. doi: 10.1002/cld.253.

28.  Provost PJ, Hilleman MR. Propagation of human hepatitis A virus in cell culture in vitro. Proc Soc Exp Biol Med. 1979;160:213–221. doi: 10.3181/00379727-160-40422.

29.  Rezende G, Roque-Afonso AM, Samuel D, Gigou M, Nicand E, Ferre V, Dussaix E, Bismuth H, Féray C. Viral and clinical factors associated with the fulminant course of hepatitis A infection. Hepatology. 2003;38:613–618. doi: 10.1053/jhep.2003.50366. 

30.  Rizzetto M. Hepatitis D Virus: Introduction and Epidemiology. Cold Spring Harb Perspect Med. 2015;5:a021576. doi: 10.1101/cshperspect.a021576. 

31.  Shepard CW, Simard EP, Finelli L, Fiore AE, Bell BP. Hepatitis B virus infection: epidemiology and vaccination. Epidemiol Rev. 2006;28:112–125. doi: 10.1093/epirev/mxj009.

32.  Stockdale AJ, Kreuels B, Henrion MYR, Giorgi E, Kyomuhangi I, de Martel C, Hutin Y, Geretti AM. The global prevalence of hepatitis D virus infection: Systematic review and meta-analysis. J Hepatol. 2020;73:523–532. doi: 10.1016/j.jhep.2020.04.008.

33.  Sümer Ş, Ural O. Akut Viral Hepatitler. In: Topçu A, Söyletir G, Doğanay M, eds. Enfeksiyon Hastalıkları ve Mikrobiyolojisi. 4. Baskı. İstanbul. Nobel Tıp Kitabevleri, 2017:1079-81.

34.  Tan A, Koh S, Bertoletti A. Immune Response in Hepatitis B Virus Infection. Cold Spring Harb Perspect Med. 2015;5:a021428. doi: 10.1101/cshperspect.a021428.

35.  Tan G, Song H, Xu F, Cheng G. When Hepatitis B Virus Meets Interferons. Front Microbiol. 2018;9:1611. doi: 10.3389/fmicb.2018.01611.

36.  Tassopoulos NC, Koutelou MG, Macagno S, Zorbas P, Rizzetto M. Diagnostic significance of IgM antibody to hepatitis delta virus in fulminant hepatitis B. J Med Virol. 1990;30:174–177. doi: 10.1002/jmv.1890300305. 

37.  Taylor RM, Davern T, Munoz S, Han SH, McGuire B, Larson AM, Hynan L, Lee WM, Fontana RJ US Acute Liver Failure Study Group. Fulminant hepatitis A virus infection in the United States: Incidence, prognosis, and outcomes. Hepatology. 2006;44:1589–1597. doi: 10.1002/hep.21439.

38.  Terrault NA, Lok ASF, McMahon BJ, et al. Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance. Hepatology. 2018;67(4):1560-99. 

39.  Thomas DL. Global Elimination of Chronic Hepatitis. N Engl J Med. 2019;380:2041–2050. doi: 10.1056/NEJMra1810477.

40.  Tillmann HL, Thompson AJ, Patel K, Wiese M, Tenckhoff H, Nischalke HD, Lokhnygina Y, Kullig U, Göbel U, Capka E, Wiegand J, Schiefke I, Güthoff W, Grüngreiff K, König I, Spengler U, McCarthy J, Shianna KV, Goldstein DB, McHutchison JG, Timm J, Nattermann J German Anti-D Study Group. A polymorphism near IL28B is associated with spontaneous clearance of acute hepatitis C virus and jaundice. Gastroenterology. 2010;139:1586–1592, 1592.e1. doi: 10.1053/j.gastro.2010.07.005.

41.  Türkiye viral hepatit önlem ve kontrol programı 2018-2023. Ankara: T.C. Sağlık Bakanlığı. [erişim 25 Kasım 2025]. https://hsgm.saglik.gov.tr/depo/Yayinlarimiz/Programlar/Turkiye_Viral_Hepatit_Onleme_ve_Kontrol_Programi_2018-2023.pdf

42.  Victor JC, Monto AS, Surdina TY, Suleimenova SZ, Vaughan G, Nainan OV, Favorov MO, Margolis HS, Bell BP. Hepatitis A vaccine versus immune globulin for postexposure prophylaxis. N Engl J Med. 2007;357:1685–1694. doi: 10.1056/NEJMoa070546. 

43.  WHO position paper on hepatitis A vaccines – October 2022 https://www.who.int/teams/immunization-vaccines-and-biologicals/policies/position-papers/hepatitis-a

44.  Wieland S, Thimme R, Purcell RH, Chisari FV. Genomic analysis of the host response to hepatitis B virus infection. Proc Natl Acad Sci U S A. 2004;101:6669–6674. doi: 10.1073/pnas.0401771101.

45.  Wieland SF, Chisari FV. Stealth and cunning: hepatitis B and hepatitis C viruses. J Virol. 2005;79:9369–9380. doi: 10.1128/JVI.79.15.9369-9380.2005. 

46.  World Health Organization. Multicountry acute,severe hepatitis of unknown origin in children.2022. https://www.who.int/emergencies/disease-outbreak-news/item/2022-DON376 Erişim: 25 Kasım 2025